Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma?
Juweid
Malik E
ME
Smith
Brian
B
Itti
Emmanuel
E
Meignan
Michel
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007167:Immunotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging* / Q000628:therapy; D049268:Positron-Emission Tomography / Q000379:methods / Q000592:standards*; D019275:Radiopharmaceuticals
D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18